Background
==========

The most recent global estimates suggest 285 million people worldwide are visually impaired, of whom, 39 million are blind \[[@B1]\]. The WHO defined Africa region has 26 million people with visual impairment (VI) of whom 6 million are blind. The continent also has the greatest disparity between numbers blind and number of ophthalmologists per million people \[[@B2]\], and therefore the greatest need for scaling up services.

In recent years several cross-sectional surveys have been undertaken across Africa to estimate prevalence and causes of blindness \[[@B3]-[@B16]\]. Whilst this information has been vital in planning services where resources and provision of healthcare are limited, data on incidence and rates of progression of eye disease are needed to allow long-term planning. To date, no longitudinal, population-based studies of eye disease have been undertaken in Africa, and there have been only ten worldwide, predominantly in high-income settings (Table [1](#T1){ref-type="table"}) \[[@B17]-[@B26]\].

###### 

Population-based cohort studies of eye disease (not exhaustive)

                **Study**                 **Location**    **Year commenced**   **Years of follow up**   **No of participants**   **Reference\***
  ------------------------------------- ---------------- -------------------- ------------------------ ------------------------ -----------------
          Beaver Dam Eye Study                USA                1988                 Baseline                   4926              \[[@B17]\]
                    5                         3684                                                                              
                   10                         2764                                                                              
                   15                         2119                                                                              
         Blue Mountain Eye Study           Australia             1992                 Baseline                   3654              \[[@B18]\]
                    5                         2335                                                                              
                   10                         1952                                                                              
             Rotterdam Study              Netherlands            1990                 Baseline                   6418              \[[@B19]\]
                    2                         4953                                                                              
                   6.5                        3406                                                                              
                   11                         2387                                                                              
        Copenhagen City Eye Study           Denmark              1986                 Baseline                   946               \[[@B20]\]
                   14                         359                                                                               
           Barbados Eye Study               Barbados             1987                 Baseline                   4631              \[[@B21]\]
                    4                         3427                                                                              
                    9                         2793                                                                              
   Pathologies Oculaires Liees a L'Age       France              1995                 Baseline                   2584              \[[@B22]\]
                    3                         1642                                                                              
   Melbourne Visual Impairment Project     Australia             1992                 Baseline                   5147              \[[@B23]\]
                    5                         3271                                                                              
             Hisayama Study                  Japan               1998                 Baseline                   1482              \[[@B24]\]
                    5                         961                                                                               
                    9                    (1401\>40 yrs)                                                                         
           Reykjavik Eye Study              Iceland              1996                 Baseline                   1045              \[[@B25]\]
                    5                         846                                                                               
      Los Angeles Latino Eye Study            USA                2000                 Baseline                   6357              \[[@B26]\]
                    4                         4658                                                                              

\*Only one reference per study given.

The current study was undertaken in Nakuru district (now Nakuru County), which is the main district of Kenya's largest province, the Rift Valley and has a population of 1.6 million. Nakuru district is broadly representative of Kenya in terms of ethnic diversity and economic activities. In 2004, a Rapid Assessment of Avoidable Blindness (RAAB) was completed in Nakuru district, to estimate the prevalence and causes of avoidable blindness and VI in the population of those 50 years and over \[[@B7]\]. A subsequent more comprehensive study was planned in the same region as a consequence of this survey to estimate causes and risk factors for those with visual impairment as well as those with non-visually impairing eye disease, with a particular focus on posterior segment eye disease \[[@B6]\].

Fieldwork was carried out in 2007 and 2008, during the course of which 4414 participants (a response rate of 88.1%) aged 50 years and above underwent ophthalmic and/or general examinations.

The prevalence of blindness and visual impairment \[[@B6]\], glaucoma, age-related macular degeneration (AMD) \[[@B27]\], diabetic retinopathy (DR), cataract, refractive error (RE) \[[@B28],[@B29]\] and cardiovascular diseases \[[@B30],[@B31]\] were assessed. This 2007/08 survey forms the baseline to cohort described here.

The overall aim of this cohort is to estimate the incidence, progression and risk factors for the development of blindness/visual impairment and their leading causes in a Kenyan adult population.

Objectives
----------

### Incidence

To estimate the age- and sex- specific incidence of visual impairment (VA \< 6/12) and blindness (VA \< 3/60) (all causes) in a Kenyan adult population.

To estimate the age- and sex- specific incidence of cataract, RE, glaucoma, AMD and DR.

### Causes & risk factors

To identify the causes and risk factors for incident visual impairment and blindness from specific diseases investigated (specifically focusing on demographic, anthropometric, behavioural, and vascular risk factors).

### Progression

To estimate the risk of progression of Cataract, RE, Glaucoma, AMD and DR among cases detected at baseline.

### Treatment & progression outcome

To describe the outcome of treatment for cataract, RE, glaucoma or DR among cases detected at baseline.

To describe the progression of untreated eye disease among cases detected at baseline.

Methods/Design
==============

This paper describes the definitions, eligibility criteria, follow-up procedures, visual acuity (VA) measurements, anthropometry and clinical examination procedures adopted for the study.

Baseline study population - sample size
---------------------------------------

The sample size of 5000 participants required for the baseline survey was calculated based on an expected prevalence of VA \< 6/12 in the better eye due to posterior segment eye diseases (PSED) of 3.0% among those aged ≥50 years, a required precision of 0.5% (i.e. a 95% confidence interval \[CI\] of 2.5%-3.5%), a design effect of 1.5, and a response rate of 90%. (Epi Info 6.04, Centers for Disease Control and Prevention, Atlanta, GA). We selected 100 clusters each of 50 participants.

Sampling strategy and recruitment
---------------------------------

Recent census data for Kenya were not available \[[@B32]\], and therefore electoral role lists that were renewed in 2006 in preparation for the 2007 general elections were used as the sampling frame for this baseline survey. The population size was updated for the year 2007 using a population growth rate of 2.7% per year \[[@B33]\]. One hundred clusters were selected with a probability proportional to the size of the population (Figure [1](#F1){ref-type="fig"}). A cluster was defined as the area served by the polling station.

![Map showing the 100 study locations in the Nakuru County, Kenya.](1471-2415-14-60-1){#F1}

Households were selected within clusters using a modified compact segment sampling method \[[@B34]\]. Each cluster was divided into segments so that each segment included approximately 50 people aged ≥ 50 years. For instance, if a cluster included 200 people aged ≥ 50 years then it was divided into four segments. One of the segments was chosen at random by drawing lots and all households in the segment were sequentially sampled, until 50 people aged ≥ 50 years were identified. An eligible individual was defined as someone aged ≥ 50 years living in the household for at least three months in the previous year. Age was determined using the subject's testimony, national identity cards and a calendar of historic events. If the segment did not include 50 people aged ≥ 50 years then another segment was chosen at random and sampling continued until 50 were reached. If after enumerating individual number 49 the next household had more than one person aged ≥50 all were enumerated and invited for examination.

Baseline findings
-----------------

In total, 4381 participants underwent complete (ophthalmic and general) examination at baseline across 100 clusters. The prevalence of blindness was 1.6% (95% CI: 1.2-2.1%) \[[@B6]\].

Follow-up
---------

A pilot follow up retraced 438 participants from 10 of the 100 clusters in 2008, a mean of 1.5 years from baseline, and 408 (79%) were successfully retraced to give an estimated 4.2% loss per year.

Retracing at follow-up - advance team
-------------------------------------

Approximately one week before the follow-up examination clinic was planned for a given cluster, a field officer studied the maps of the village and made phone contact with the village chief or guide to arrange the visit. At the planning visit a list of study participants were given to the chief and a local village guide was recruited to assist location of the study participants. At this visit the examination site was established and identification of amenities such as electricity, water and road access were made. Two days prior to the clinic, the field officer reminded chiefs of the visit by phone and notified them and the guide of the advance team's arrival.

On the day prior to the examination clinic, the Advance Team visited homes of baseline participants and confirmed their identity using National Identity cards. The two advance teams comprised of one nurse, one field officer and a driver or public transport. During this visit they performed the following duties:

`○` Located individuals with assistance from the guide, phone numbers when available and previously recorded GPS locations using a Garmin Oregon 450 Satellite Navigation device.

`○` Explained details of the exam and obtain written/thumb print informed consent for examination

`○` Informed selected participants about location and time for examination

Registration
------------

On the examination day, the advance team confirmed the identity of participants against their records from the previous day and against data from baseline (age, date of birth, name, and identity cards). Each participant was given a questionnaire, which was completed by the examiners as they move from station to station.

Examination procedures
----------------------

Examinations were performed as per baseline unless otherwise indicated in Table [2](#T2){ref-type="table"}.

###### 

Instruments used at baseline and follow-up for examination, including rationale for change where appropriate

  **Procedure**                                                            **Baseline Instrument (2007/08)**                                                                 **Follow-up instrument (2013/14)**                                                                                                     **Rationale for change**
  ------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------
  Near Vision Test                                                         Continuous Text "Read in Style®" diopter chart                                                    Unchanged                                                                                                                              N/A
  Personal Interview                                                       Questionnaire developed by the survey ophthalmologist (WM)                                        Questionnaire developed by the survey ophthalmologist (AB) see Additional file [1](#S1){ref-type="supplementary-material"}: Appendix   N/A
  Weight                                                                   The Seca 761 Medical Class 4 Scales mechanical ground scale (Williams Medical Supplies, London)   Tanita Segmental Body Composition Monitor                                                                                              Combined weight and bioimpedence device -- approved for medical studies
  Bioimpedence                                                             Not performed                                                                                     Tanita Segmental Body Composition Monitor                                                                                              Combined weight and bioimpedence device -- approved for medical studies
  Height                                                                   Leicester Height Measure (Stadiometer) (Chasmors Ltd, London)                                     SECA Height Measure                                                                                                                    Better stability on uneven grounds
  Waist and Hip circumference                                              Chasmors WM02 Body Tape measure                                                                   SECA Measuring tape                                                                                                                    Availability
  Blood pressure                                                           Omron® Digital Automatic Blood Pressure Monitor Model HEM907                                      Unchanged                                                                                                                              N/A
  Visual Acuity                                                            ETDRS LogMAR chart                                                                                Unchanged                                                                                                                              N/A
  Auto refraction                                                          Topcon® Auto refractor RM8800                                                                     Welch Allyn SureSight                                                                                                                  Improved portability
  Corrected Visual Acuity                                                  Frames and standard refraction lenses                                                             Unchanged                                                                                                                              N/A
  Undilated eye exam including imaging (SL-OCT)                            Haag-Streit® Slit lamp BD900 with SL-OCT                                                          Haag-Streit® Slit lamp BM900 -- no SL-OCT                                                                                              Availability
  Tonometry                                                                Haag Streit® Goldmann Applanation tonometer on above slit lamp                                    Haag Streit® Goldmann Applanation tonometer on above slit lamp                                                                         N/A
  Gonioscopy                                                               Not performed                                                                                     Four-mirror non-coupling gonioscopy lens (Zabby's)                                                                                     For glaucoma sub-typing and angle evaluation in normal population
  Visual fields                                                            Humphrey Field Analyzer II -720 *i* series(Zeiss®)                                                Henson 8000 Visual Field Analyser (TopCon, Inc)                                                                                        Deemed more suitable for epidemiological data collection
  Pupil Dilation                                                           Mydriacyl drops (Alcon®)                                                                          G. Tropicamide 1% + G. Phenylepherine 2.5% (Minims)                                                                                    Single units and better shelf life
  Blood sugar                                                              Accutrend GCT and test strips (Roche®)                                                            OneTouch Select, Lifescan                                                                                                              Availability. Approved for medical studies
  Blood Cholesterol                                                        Accutrend GCT and test strips (Roche®)                                                            Not performed                                                                                                                          Cost prohibited inclusion
  HbA1c                                                                    Not performed                                                                                     (A1C Now+, Bayer)                                                                                                                      Increase accuracy of Diabetes Mellitus diagnosis as participants non-fasted
  Examination of anterior and posterior segments through a dilated pupil   90D lens and slit lamp(Volk®)                                                                     Superfield and 60D Lens (Volk) and Slit Lamp                                                                                           Study ophthalmologist preference
  Retinal Photo                                                            Topcon® NW6S Non Mydriatic camera model                                                           Haag-Streit DRS Retinal Camera                                                                                                         Suitability for travel and ease of use.

Details of each examination station are provided below including differences, if there were any, between baseline and follow-up.

Anthropometry
-------------

A nurse performed and recorded measures of participants: height; weight; waist and hip circumference, and three measures of blood pressure, each 5 minutes apart. In addition, at follow-up, bioimpedence (Tanita Segmental Body Composition Monitor) was performed.

At baseline, capillary blood was taken from all participants for random blood glucose and cholesterol. At follow-up, no blood for cholesterol was collected and in addition, subjects with a random blood sugar greater than 11.1 mmol/L (IDF guidance at time of baseline study), those with known diabetes (regardless of random measure), evidence of diabetic retinopathy on retinal imaging and a subset (chosen randomly within each cluster) with random glucose between 7-11 mmol/L had an additional capillary blood HbA1c (A1C Now+, Bayer).

Interview
---------

An interviewer performed the structured interview in the participant's preferred language covering i) demographic details including; name, year of birth, ethnicity and education level; ii) past medical and ocular history including medical or ophthalmic medication or surgery and relevant family history; iii) relevant risk factors including; smoking and tobacco consumption and alcohol intake; iv) socioeconomic status based on job, housing conditions, ownership of material goods and livestock which is translated in to a score based on previous work in the same population \[[@B35]\]. (See Additional file [1](#S1){ref-type="supplementary-material"}: Appendix for Questionnaire/Data Entry Booklet).

Visual acuity
-------------

A clinical officer determined whether the study participant:

a\) Attends wearing distance correction glasses

b\) Owns distance correction glasses but failed to bring them

c\) Does not have any distance glasses

d\) Routinely uses reading glasses

e\) Attends wearing aphakic glasses

Visual acuity (VA) was measured using a back-illuminated modified LogMAR reduced tumbling E chart \[[@B36],[@B37]\], which has been used in previous population based studies \[[@B38],[@B39]\].

Autorefraction
--------------

All subjects, regardless of VA underwent autorefraction using the Topcon® Auto refractor RM8800 at baseline and the hand held SureSight autorefractor (Welch Allyn) at follow-up, following manufacturers guidelines. Any subject recording an acuity of ≤24 optotypes, \<6/9 equivalent (with or without glasses) underwent best corrected visual acuity. The refraction measure recorded for each eye was mounted in the trial frames using trial lenses (rounded up or down to the nearest 0.25 diopters). Visual acuity was then re-measured to give an estimate of the "corrected visual acuity" in each eye individually. When autorefraction results were not available, the pinhole method was used to estimate corrected visual acuity. A subset of participants also underwent manual refraction by a visiting optometrist for five clusters to validate the accuracy of the autorefractor.

Visual field assessment
-----------------------

At baseline, all individuals with suspect or abnormal discs on clinical examination underwent automated visual field testing. The Humphrey® Field Analyzer II - 720*i* series (Carl Zeiss Ophthalmic Systems, Inc.) was used. A suspect or abnormal disc was defined as a vertical cup/disc ratio (VCDR) of 0.7 or above; optic disc cupping asymmetry between the eyes of more than 0.2 VCDR; or any other abnormal features. A random sample of five individuals per cluster (10%) also underwent visual field testing to provide normative data.

Participants performed the Swedish Interactive Thresholding Algorithm (SITA) STANDARD 24--2. SITA Fast was used to determine the threshold level in all participants having visual field analysis. Appropriate corrective lenses for refractive errors were used when needed. An automated fixation monitor was used throughout. If the SITA fast test was reliable (following manufacturers guidelines) the SITA standard test was performed. If the SITA fast was unreliable then this was repeated once. If it remained unreliable then no further testing was done.

At follow-up, a different strategy for visual field testing was used: All subjects with VA equivalent to \> =6/60 Snellen underwent automated visual field testing by a trained visual field technician using the Henson 8000 Visual Field Analyser (TopCon, Inc.) The multiple stimulus suprathreshold test was used following manufacturers guidelines (Screening test - 26 test locations). When one or more spots were missed, the 26-point test was repeated for that eye. If any missed spots re-occurred on the second time of testing the test for that eye was extended to 68 test locations. This machine and strategy were used in preference to the baseline methods due to feedback from both patient's and tester at baseline. Patient's found the baseline testing protocol difficult to understand and the time required to complete the test meant only a sub-sample of the population could be investigated.

Slit lamp biomicroscopy examination
-----------------------------------

Undilated (anterior segment) and dilated (posterior segment) slit lamp biomicroscopy examination were performed on all participants by the study ophthalmologists (WM at baseline, AB at follow-up) using a Haag-Streit BD 900 Slit Lamp (BM 900 at follow-up) and Volk condensing lenses (90D at baseline, Superfield and 66D at follow-up).

### Anterior segment

The anterior segment of the eye was assessed for the presence of signs of trachoma. In addition at follow up examination included grading of corneal scarring, pterygium, secondary glaucoma, evidence of past or active uveitis, or evidence of surgery. The angle at baseline and follow-up was assessed using the Van Herick Test \[[@B40]\] and direct visualization of the angle using gonioscopy (performed after intraocular pressure, see below) was performed at follow-up.

At follow-up, the ophthalmologist using a bright LED pen torch tested for the Relative Afferent Pupil Defect (RAPD). RAPD was recorded as present or absent. If present it was sub-categorised in to "subtle" or "definite".

### Intraocular pressure

Goldmann Applanation Tonometry (GAT) was used to measure intraocular pressure (IOP). A drop of Proxymethacaine and fluorescein (minims) were instilled to each eye. After 20 seconds the GAT was used in combination with a slit lamp to measure the IOP in each eye. The GAT's calibration was checked as per manufacturers instructions on a daily basis by the study ophthalmologist, if found to be inaccurate, the spare GAT was used whilst the original was returned to the factory for calibration. One reading was taken from each eye and the GAT was disinfected between patients.

### Gonioscopy

Assessment of the opening angle of participants' right and left eyes was made using a four-mirror gonioscopy lens (Zabbys). This lens does not require coupling fluid and was chosen to minimize impact on the quality of retinal photographs. Angles were recorded using standard Shaffer grading \[[@B41]\] and further classified as "open", "occludable" or "closed" based on standard referral criteria. Occludable angles are defined as: pigmented trabecular meshwork not visible in 3⁄4 or more of angle circumference in primary position without manipulation, in presence of low illumination. If the patient could not cooperate with gonioscopy, the Van Herick (VH) technique \[[@B40]\] was used for grading.

Dilated slit lamp examination
-----------------------------

Pharmacologic dilation of the subject's pupils was achieved by using tropicamide 1% (Mydriacyl) with phenylephrine hydrochloride 2.5% if needed. Dilation was not performed in subjects deemed at risk of narrow angle closure (inability to visualise at least 180**°** of posterior pigmented trabecular meshwork on non-indentation gonioscopy \[[@B42]\]). At risk subjects were referred to the Nakuru Eye Unit for prophylactic laser peripheral iridotomies.

### Lens

The WHO simplified system for lens grading was used \[[@B43]\] following standard protocols. The lens was also examined for position, the presence of hyper mature (Morgagnian) cataract, and previous lens surgery (aphakic or pseudophakic). A red reflex lens image was taken when each participant was having retinal photographs. At follow-up, pseudophakic participants were assessed for the presence or absence of posterior capsular opacification and, if present, whether it entered the visual axis.

### Optic disc

The optic nerve head was examined using a 90 Diopter Lens (Volk) at the slit lamp at baseline and a 66 Diopter lens (Volk) at follow-up. The clarity of the optic nerve head was determined and graded as clear, hazy or no view. Among subjects in whom an adequate view of the disc was obtained, the VCDR was estimated and recorded for each eye. Other glaucomatous changes were recorded and non-glaucomatous characteristics such as optic atrophy and optic pits were also recorded.

### Macula

The macula was examined using a 90 Diopter Lens (Volk) at the slit lamp at baseline and a 66 Diopter or Superfield lens (Volk) at follow-up. The view of the macula was recorded as clear, hazy or no view. DR was clinically graded and recorded as absent, non proliferative, proliferative and end stage or maculopathy (macula oedema) \[[@B44]\]. The presence of drusen, hypo or hyper pigmentation, dry or geographic atrophy and neovascular changes were also recorded.

Fundus photography
------------------

An Ophthalmic Assistant performed digital photography of the lens and fundus on all study participants using a Topcon® NW6S Non Mydriatic camera model at baseline and DRS Digital Fundus Camera (Haag-Streit) at follow-up. The study ophthalmologist checked images were of sufficient quality for grading in the absence of prominent media opacities. An anterior segment co-axial photograph was taken for lens grading from each eye. Two 45**°** fundus photographs were taken in each eye, one optic disc centered and the other macula centered. Images were then securely uploaded to the Moorfields Reading Centre for review and grading for image quality, the presence or absence of pathology and the severity of pathology when present.

Note: The gold-standard for grading of DR, AMD and optic disc changes is based on retinal photographs and not clinical assessment. Clinical examination was performed as a backup to equipment failure and a comparison of clinical and image based grading can be compared in the analysis stage and factored in the scenario by which a number of participants only have clinical grading available.

Data management and analysis
----------------------------

A patient record was completed for each participant and crosschecked for errors by the project field coordinator. Patient records were scanned to create a digital backup and then data were entered into an EpiData database (with built in range and consistency checks) independently by two data clerks and validated by the study ophthalmologist to reconcile any differences. Further data cleaning and all statistical analyses were conducted using STATA 10.0 (StataCorp LP, Texas, USA).

The visual fields PDF print outs and raw data were sent securely to Moorfields Eye Hospital for grading along with the fundus and anterior segment images at baseline and follow-up. All image and visual field data were backed up on local devices and external hard drives. All images were first examined for quality and categorized as excellent, good, fair, borderline and ungradeable. If the images were ungradeable the clinical diagnosis was used. For gradable images the retina and optic disc were reviewed, and a diagnosis made based on the appearance of the image e.g. diabetic retinopathy, toxoplasmosis, onchocerciasis, age related macular degeneration, myopic fundus, glaucoma, optic atrophy or other retinal pathology. VCDR was measured and all images were graded for the absence/presence and stage of DR and ARMD. The graders graded the images for as many disease categories as possible, and so if it was feasible to grade an image for optic disc abnormality but not for ARMD, then the grader completed the optic disc grading only. A senior grader verified a random 10% of images that were graded as normal as well as all abnormal images to ensure quality assurance. The graders re-graded a random selection of images with a minimum of 14-days interval to allow for intragrader reliability to be established.

Definitions used for analysis are detailed in Table [3](#T3){ref-type="table"}.

###### 

Definitions of disease incidence and progression

                                                                     **Disease**                                                                                                               **Incidence**                                                                                                             **Progression**                                                                                                                                                                                                                               
  ------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------
                                                      **Blindness and Visual Impairment (VI)**                                                                        Blind: Persons with VA of ≥3/60 in the better eye at baseline.                                         Persons who have VA of \<3/60 in the better eye at follow up who had ≥3/60 in the better eye at baseline                       Categorical changes in visual acuity between: Normal; Mild VI; Moderate VI; Severe VI; Blind, with a minimum of two line Snellen equivalent change in VA.  
                                                                    **Cataract**                                                                     Persons without evidence of cataract at baseline based on WHO simplified cataract grading systems   Persons with evidence of cataract at follow-up based on WHO simplified cataract grading systems \[[@B45]\] who did not have evidence at baseline                          Persons with evidence of any grade of cataract at baseline based on WHO simplified cataract grading systems                                                Persons who increase by two or more severity grades in each sub-type of cataract.
                                                           **Primary open angle glaucoma**                                                                 Persons without glaucoma in either eye at baseline based on ISGEO \[[@B46]\] criteria                                    Persons who develop ISGEO classification 1, 2 or 3 glaucoma by the 6-year follow-up point                                                                                     Glaucoma or glaucoma suspect case at baseline                                                                                          Definite, disc or field progression. See below\* \[[@B47]\]
                                                         **Age-related macula degeneration**                                                                       Persons who did not have any evidence of AMD at baseline in both eyes                                                           Persons with evidence of early, late or specific AMD lesions                                                                                        AREDS \[[@B48]\] step 9 or less (no AMD or early AMD) at baseline.                                               2-or-more-step increase in combined AREDS score from baseline in persons with gradable fundus photographs at both time points.
                                                              **Diabetic retinopathy**                                                               Persons with diabetes and free of retinopathy at baseline and persons developing DM by follow up.                                                     Persons with signs of DR (ETDRS) \[[@B49]\]                                                                                                    Persons with diabetes and minimal or moderate DR at baseline                                                                                   \(1\) Persons who develop severe DR by the 6-year follow-up
                                               CSME and incidence of proliferative or severe DR^**ϒ**^                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   \(2\) Increase by ≥ 3 steps on the ETDRS Severity Scale or development of proliferative DR necessitating photocoagulation therapy or vitrectomy                                                                                                                                                                                                                                                                                                                                                                                                                     

\**Definite progression* will be defined as those with a combination of ≥0.2 VCDR increase in either eye and/or ≥0.2 VCDR asymmetry between the two eyes with a corresponding progression on the visual field test defined as (TBC -- either "expert analysis" or an arbitrary objective measure).

Note: More specific definitions will be provided in subsequent papers.

Quality assurance procedures
----------------------------

### Training

Inter observer variations (IOV) assessments were performed in the training phase. IOV assessments on anthropometric variables were done by having the two nurses perform repeat measuring of 50 subjects. IOV of visual acuity were undertaken by having the ophthalmic clinical officer (OCO) and ophthalmic nurse repeat measures of 50 subjects (half normal vision and half visual impairment). IOV of undilated examinations were done by repeat measure of 50 subjects (half normal vision and half visual impairment) by a visiting ophthalmologist and study ophthalmologist at the beginning of the baseline survey and again in the middle. IOV of dilated exams were done by repeat measure of 50 subjects (half normal vision and half visual impairment) by a visiting ophthalmologist and study ophthalmologist at baseline. Retraining was done where IOV scores indicated poor comparability (kappa \< 0.5).

At follow-up, four weeks of training in November/December 2012 was completed for the study team members on all equipment and study protocols. Three pilot clusters examining over one hundred people were completed prior to commencing the study.

Standard Operating Procedures (SOP) detailing follow-up survey methodology for each examination station were prepared and read by all study team members. The SOP was used in training and for reference during fieldwork. Supervisory visits were made to the field site (HK and MJB) to monitor practices and ensure standard protocols were being followed.

Non-responders at follow-up
---------------------------

Participants who were examined at baseline and eligible for follow-up assessment but who did not attend the examination clinic were contacted to determine the reason for their absence. Participants who were not locatable for the examination were categorized as non-responders and their reason for absence determined through available phone contact, neighbors and village guides as, "deceased", "moved away", or "unknown".

Service provision
-----------------

All participants identified with treatable disease in the study were offered appropriate care including free surgery and transport to the Rift Valley General Provinical Hospital or St Mary's mission hospital, Elementita. Specific cases requiring other services were referred to the Kikuyu Eye Unit. A trained ophthalmic nurse or Ophthalmic Clinical Officer (OCO) discussed the diagnosis and the treatment options available to subjects diagnosed with untreatable eye disease. As well as study participants, non-study attendees were examined and treated by the study team.

Ethical approval
----------------

The study adhered to the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of London School of Hygiene and Tropical Medicine at both baseline and follow-up. Baseline approval was provided by the Kenya Medical Research Institute and the African Medical and Research Foundation (AMREF), Kenya at follow-up. At both phases approval was also granted by the Rift Valley Provincial Medical Officer and the Nakuru district Medical Officer of Health. Approval was sought from the administrative heads in each cluster, usually the village chief. They were also given a copy of the consent form to read and pass on to those in the village.

Informed consent
----------------

Informed consent was obtained from all participants. The objectives of the survey and the examination process were explained to those eligible in the local dialect, in the presence of a witness. A subject was examined only after informed consent was obtained. All participants gave written (or thumbprint) consent to participate.

Discussion
==========

The Nakuru Eye Disease Cohort Study is the first population-based cohort study of eye disease to have taken place in Africa. It will provide estimates on the incidence of blindness and visual impairment, the incidence and progression of: cataract, refractive error, glaucoma, ARMD and DR as well other retinal conditions. This data will be disseminated to eye care providers and programs in the region to facilitate the provision of eye care services.
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